Julian M M Rogasch

List of Publications by Year
in descending order

41 papers	454 citations	687363 13 h-index	752698 20 g-index
46 all docs	46 docs citations	46 times ranked	782 citing authors

#	Article	IF	Citations
1	Quantitative assessment of the asphericity of pretherapeutic FDG uptake as an independent predictor of outcome in NSCLC. BMC Cancer, 2014, 14, 896.	2.6	40
2	Pretherapeutic FDG-PET total metabolic tumor volume predicts response to induction therapy in pediatric Hodgkin's lymphoma. BMC Cancer, 2018, 18, 521.	2.6	39
3	Reconstructed spatial resolution and contrast recovery with Bayesian penalized likelihood reconstruction (Q.Clear) for FDG-PET compared to time-of-flight (TOF) with point spread function (PSF). EJNMMI Physics, 2020, 7, 2.	2.7	39
4	The influence of different signal-to-background ratios on spatial resolution and F18-FDG-PET quantification using point spread function and time-of-flight reconstruction. EJNMMI Physics, 2014, 1, 12.	2.7	36
5	Intermediate-term outcome after PSMA-PET guided high-dose radiotherapy of recurrent high-risk prostate cancer patients. Radiation Oncology, 2017, 12, 140.	2.7	34
6	The association of tumor-to-background ratios and SUVmax deviations related to point spread function and time-of-flight F18-FDG-PET/CT reconstruction in colorectal liver metastases. EJNMMI Research, 2015, 5, 31.	2.5	29
7	Contrast-enhanced ultrasound (CEUS) of cystic renal lesions in comparison to CT and MRI in a multicenter setting. Clinical Hemorheology and Microcirculation, 2020, 75, 419-429.	1.7	21
8	Assessment of the tibial slope is highly dependent on the type and accuracy of the preceding acquisition. Archives of Orthopaedic and Trauma Surgery, 2019, 139, 1691-1697.	2.4	20
9	Evaluation of T1 relaxation time in prostate cancer and benign prostate tissue using a Modified Look-Locker inversion recovery sequence. Scientific Reports, 2020, 10, 3121.	3.3	17
10	A direct comparison of contrast-enhanced ultrasound and dynamic contrast-enhanced magnetic resonance imaging for prostate cancer detection and prediction of aggressiveness. European Radiology, 2018, 28, 1949-1960.	4.5	16
11	Prognostic value of baseline [18F]-fluorodeoxyglucose positron emission tomography parameters MTV, TLG and asphericity in an international multicenter cohort of nasopharyngeal carcinoma patients. PLoS ONE, 2020, 15, e0236841.	2.5	15
12	Degenerative changes after posterior cruciate ligament reconstruction are irrespective of posterior knee stability: MRI-based long-term results. Archives of Orthopaedic and Trauma Surgery, 2018, 138, 377-385.	2.4	14
13	The association of intra-therapeutic heterogeneity of somatostatin receptor expression with morphological treatment response in patients undergoing PRRT with [177Lu]-DOTATATE. PLoS ONE, 2019, 14, e0216781.	2.5	14
14	Moving the goalposts while scoring―the dilemma posed by new PET technologies. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 2696-2710.	6.4	13
15	Standardized visual reading of F18-FDG-PET in patients with non-small cell lung cancer scheduled for preoperative thoracic lymph node staging. European Journal of Radiology, 2016, 85, 1345-1350.	2.6	10
16	Dual time point imaging for F18-FDG-PET/CT does not improve the accuracy of nodal staging in non-small cell lung cancer patients. European Radiology, 2016, 26, 2808-2818.	4.5	10
17	The Prognostic Value of the De Ritis Ratio for Progression-Free Survival in Patients with NET Undergoing [177Lu]Lu-DOTATOC-PRRT: A Retrospective Analysis. Cancers, 2021, 13, 635.	3.7	10
18	Influences on PET Quantification and Interpretation. Diagnostics, 2022, 12, 451.	2.6	9

#	ARTICLE	IF	CITATIONS
19	Asphericity of Somatostatin Receptor Expression in Neuroendocrine Tumors: An Innovative Predictor of Outcome in Everolimus Treatment?. Diagnostics, 2020, 10, 732.	2.6	7
20	Detection of obstructive uropathy and assessment of differential renal function using two functional magnetic resonance urography tools. Nuklearmedizin - NuclearMedicine, 2017, 56, 39-46.	0.7	6
21	FDG-PET/CT for pretherapeutic lymph node staging in non-small cell lung cancer: A tailored approach to the ESTS/ESMO guideline workflow. Lung Cancer, 2021, 157, 66-74.	2.0	6
22	An optimized imaging protocol for [99mTc]Tc-DPD scintigraphy and SPECT/CT quantification in cardiac transthyretin (ATTR) amyloidosis. Journal of Nuclear Cardiology, 2021, 28, 2483-2496.	2.1	6
23	Explorative analysis of a score predicting the therapy response of patients with metastatic, castration resistant prostate cancer undergoing radioligand therapy with 177Lu-labeled prostate-specific membrane antigen. Annals of Nuclear Medicine, 2021, 35, 314-320.	2.2	6
24	Diffusion-weighted magnetic resonance imaging using a preclinical 1ÂT PET/MRI in healthy and tumor-bearing rats. EJNMMI Research, 2019, 9, 21.	2.5	5
25	Selective Internal Radiation Therapy in Breast Cancer Liver Metastases: Outcome Assessment Applying a Prognostic Score. Cancers, 2021, 13, 3777.	3.7	5
26	Interobserver variability of image-derived arterial blood SUV in whole-body FDG PET. EJNMMI Research, 2019, 9, 23.	2.5	4
27	Validation of Independent Prognostic Value of Asphericity of 18F-Fluorodeoxyglucose Uptake in Nonâ€"Small-Cell Lung Cancer Patients Undergoing Treatment With Curative Intent. Clinical Lung Cancer, 2020, 21, 264-272.e6.	2.6	3
28	Shortened Tracer Uptake Time in GA-68-DOTATOC-PET of Meningiomas Does Not Impair Diagnostic Accuracy and PET Volume Definition. Diagnostics, 2020, 10, 1084.	2.6	3
29	PET measured hypoxia and MRI parameters in re-irradiated head and neck squamous cell carcinomas: findings of a prospective pilot study. F1000Research, 2020, 9, 1350.	1.6	3
30	Comparison of glomerular filtration rate (GFR) with Tc-99m-DTPA and tubular extraction rate (TER) with Tc-99m-MAG3 in potential living kidney donors: Feasibility of a one-day protocol. Nuklearmedizin - NuclearMedicine, 2019, 58, 460-469.	0.7	3
31	Individualized risk assessment in neuroblastoma: does the tumoral metabolic activity on 123I-MIBG SPECT predict the outcome?. European Journal of Nuclear Medicine and Molecular Imaging, 2017, 44, 2203-2212.	6.4	2
32	I-123-MIBG scintigraphy in patients with neuroblastoma. Nuklearmedizin - NuclearMedicine, 2018, 57, 35-39.	0.7	2
33	Asphericity of tumor FDG uptake in non-small cell lung cancer: reproducibility and implications for harmonization in multicenter studies. EJNMMI Research, 2020, 10, 134.	2.5	2
34	Prognostic Value of the Largest Lesion Size for Progression-Free Survival in Patients with NET Undergoing Salvage PRRT with [177Lu]Lu-DOTATOC. Cancers, 2022, 14, 1768.	3.7	2
35	Reply to Paulo Schiavom Duarte. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 3024-3025.	6.4	1
36	Influence of rigid coregistration of PET and CT data on metabolic volumetry: a userâ€™s perspective. EJNMMI Research, 2013, 3, 85.	2.5	0

#	Article	IF	Citations
37	A Novel Tracer for GD2-Positive Neuroblastoma. , 2019, 58, .		0
38	Title is missing!. , 2020, 15, e0236841.		0
39	Title is missing!. , 2020, 15, e0236841.		0
40	Title is missing!. , 2020, 15, e0236841.		0
41	Title is missing!. , 2020, 15, e0236841.		0